Onkologie. 2024:18(1):10-12 | DOI: 10.36290/xon.2024.002

Surgical management of ovarian cancer

Munachiso Ndukwe1, Ivan Práznovec1, Martin Štěpán1, Klára Kolářová1, Denisa Pohanková2, Jiří Špaček1
1 Porodnická a gynekologická klinika, Lékařská fakulta, Univerzita Karlova v Hradci Králové a Fakultní nemocnice, Hradec Králové
2 Klinika onkologie a radioterapie, Lékařská fakulta, Univerzita Karlova v Hradci Králové a Fakultní nemocnice, Hradec Králové

Ovarian cancer is a heterogeneous group of diseases with an overall poor prognosis, whose treatment is necessary to manage well keeping in mind the quality of life and overall survival of the patient. Preoperative diagnosis and treatment in a multidisciplinary setting play an important role in setting the optimal treatment strategy. Surgical treatment in the early stages of ovarian cancer has a curative and staging purpose while in advanced stages it has primarily a goal of optimal resection of macroscopic tumors. Surgical treatment of ovarian cancer should be performed by experienced gynecological oncologists in centers with expertise. The discussion between primary cytoreductive surgery versus interval cytoreductive surgery in advanced ovarian cancer remains very active and alive, however surgical treatment remains the gold standard of treatment in ovarian cancer, the extension and radicality of which needs to be always individualized.

Keywords: ovarian cancer, staging surgery, cytoreductive surgery, fertility sparing surgery.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ndukwe M, Práznovec I, Štěpán M, Kolářová K, Pohanková D, Špaček J. Surgical management of ovarian cancer. Onkologie. 2024;18(1):10-12. doi: 10.36290/xon.2024.002.
Download citation

References

  1. McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80:762-778. Go to original source...
  2. Erickson BK, Conner MG, Landen CN. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209:409-414. Go to original source... Go to PubMed...
  3. Kurman RJ, Shih I-M. The Dualistic Model of Ovarian Carcinogenesis. Am J Pathol. 2016;186:733-747. Go to original source... Go to PubMed...
  4. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615. Go to original source... Go to PubMed...
  5. Kaldawy A, Segev Y, Lavie O, et al. Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016;143:433-438. Go to original source... Go to PubMed...
  6. Moschetta M, George A, Kaye SB, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27:1449-1455. Go to original source... Go to PubMed...
  7. Ladislav D, Jan M, Miroslav K, et al. Epidemiologie zhoubných nádorů v České republice. Available from: https://portal.med.muni.cz/clanek-583-epidemiologie-zhoubnych-nadoru-v-ceske-republice.html.
  8. Lockley M, Stoneham SJ, Olson TA. Ovarian cancer in adolescents and young adults. Pediatr Blood Cancer. 2019; 66:e27512. Go to original source... Go to PubMed...
  9. Schindler AE. Benefits and risks of ovarian function and reproduction for cancer development and prevention. Gynecol Endocrinol. 2011;27:1043-1047. Go to original source... Go to PubMed...
  10. Pietragalla A, Arcieri M, Marchetti C, et al. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. Int J Gynecol Cancer. 2020;30:1803-1810. Go to original source... Go to PubMed...
  11. Eccles DM, Balmaña J, Clune J, et al. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review. Adv Ther. 2016;33:129-150. Go to original source... Go to PubMed...
  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer J Clin. 2020;70:7-30. Go to original source... Go to PubMed...
  13. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer. 2007;109: 221-227. Go to original source... Go to PubMed...
  14. Colombo N, Parma G, Zanagnolo V, et al. Management of Ovarian Stromal Cell Tumors. J Clin Oncol. 2007;25:2944-2951.Další literatura u autora a na www.onkologiecs.cz Go to original source... Go to PubMed...
  15. Forstner R, Sala E, Kinkel K, et al. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20: 2773-2780. Go to original source... Go to PubMed...
  16. Fischerová D. Recommended guidelines of diagnosis for women with an ovarian cyst or tumour. Ceska Gynekol. 2014;79:477-486.
  17. Javadi S, Ganeshan DM, Qayyum A, et al. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. AJR Am J Roentgenol. 2016;206:1351-1360. Go to original source... Go to PubMed...
  18. Tanoglu FB, Cetin C and Kiran G. 2022-RA-275-ESGO Comparison of patients with trucut biopsy, acid cytology with final pathology results from patients operated with prediagnose of ovarian cancer. Ovarian cancer. 2022;A227.1-A227. Go to original source...
  19. Bois A du, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115:1234-1244. Go to original source... Go to PubMed...
  20. Falzone L, Scandurra G, Lombardo V, et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). Int J Oncol. 2021;59:53. Go to original source... Go to PubMed...
  21. Colombo N, Sessa C, Bois A du, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol cancer: Off J Int Gynecol Cancer Soc. 2019;29:728-760. Go to original source... Go to PubMed...
  22. Kudela M, Marek R, Pilka R, et al. Benefits and the accuracy of the intra-operative frozen section at suspected ovarian tumours. Ceska Gynekol. 2015;80:250-255.
  23. Asp M, Peber E, Kannisto P, et al. Ovarian tumor frozen section, a multidisciplinary affair. Acta Oncol. 2022;61:785-792. Go to original source... Go to PubMed...
  24. Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer. 2017;27:1534-1542. Go to original source... Go to PubMed...
  25. Michel E, Kamga AM, Amet A, et al. Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d'Or Registry of Gynecological Cancers from 1998 to 2015. Bull du Can­cer. 2023;110:352-359. Go to original source... Go to PubMed...
  26. Vergote I, Brabanter JD, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182. Go to original source... Go to PubMed...
  27. Fagotti A, Perelli F, Pedone L, et al. Current Recommendations for Minimally Invasive Surgical Staging in Ovarian Cancer. Curr Treat Options Oncol. 2016;17:3. Go to original source... Go to PubMed...
  28. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for Stage I ovarian carcinoma in women of childbearing age. BJOG: Int J Obstet Gynaecol. 1997;104:1030-1035. Go to original source... Go to PubMed...
  29. Svobodová P. Fertility-sparing management in women with endometrial and ovarian cancers. Onkologie. 2018;12:273-277. Go to original source...
  30. Bentivegna E, Gouy S, Maulard A, et al. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol. 2016;27:1994-2004. Go to original source... Go to PubMed...
  31. Canlorbe G, Chabbert-Buffet N, Uzan C. Fertility-Sparing Surgery for Ovarian Cancer. J Clin Med. 2021;10:4235. Go to original source... Go to PubMed...
  32. Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30:1657-1664. Go to original source... Go to PubMed...
  33. Pinto P, Burgetova A, Cibula D, et al. Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review. Cancers. 2023;15:1904. Go to original source... Go to PubMed...
  34. Filis P, Mauri D, Markozannes G, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO open. 2022;7:100586. Go to original source... Go to PubMed...
  35. Gaba F, Blyuss O, Chandrasekaran D, et al. Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis. Diagnostics. 2023;13:3484. Go to original source... Go to PubMed...
  36. Kefleyesus A, Bhatt A, Escayola C, et al. Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients. Front Oncol. 2023;13:1204886. Go to original source... Go to PubMed...
  37. Armbrust R, Chekerov R, Sander S, et al. Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients. Arch Gynecol Obstet. 2022;305:963-968. Go to original source... Go to PubMed...
  38. Daniele A, Ferrero A, Fuso L, et al. Palliative care in patients with ovarian cancer and bowel obstruction. Support Care Cancer. 2015;23:3157-3163. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.